Arbutus Biopharma

Arbutus (Nasdaq: ABUS) is a biopharma company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection.

[Arbutus Biopharma @ArbutusBio]

$ABUS announced that Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloidosis.
https://t.co/Yi1qKbPayU

[Arbutus Biopharma @ArbutusBio]

$ABUS announced that it will present at the 2018 Wedbush PacGrow Healthcare Conference on August 15, 2018 at 2:30 p.m. ET. A live webcast of the presentation can be accessed via the Investors section, under Events and Presentations of Arbutus' website.
https://t.co/WXNH4dDVtN

[Arbutus Biopharma @ArbutusBio]

$ABUS announced that it will present at the first annual @Roivant #Pipeline Day on July 10, 2018, at 4:00 p.m. ET. A live webcast will be available via the Investors section, under Events and Presentations of Arbutus' website. https://t.co/5axXUKzA1z

[Arbutus Biopharma @ArbutusBio]

#HepB is the most common serious #liver infection in the world. The #HepB virus attacks liver cells and can lead to liver cancer or liver failure.

[Hep B Foundation @HepBFoundation]

#Hepatitis B is called a "silent infection" because most people do not have any symptoms when they are first infected. #hepB #HBV #heptitisB https://t.co/TXgtuiJeJq

[Arbutus Biopharma @ArbutusBio]

#DYK that #hepB symptoms usually appear 3 to 4 months after a person gets the virus? But sometimes you may not even see symptoms! Learn more here: https://t.co/32llJdaXfq

[NOhep @NO_hep]

This #WDHD2018 download the NOhep Advocacy Toolkit - https://t.co/l9lz6uN1v0. #NOhep ​https://t.co/VNBiDgdCkW

[Arbutus Biopharma @ArbutusBio]

The #HepB virus can survive outside the body for 7 days and still be capable of causing infection. You can learn more here: https://t.co/2uqfx8CdFM #HepatitisAwarenessMonth

[Arbutus Biopharma @ArbutusBio]

1,800 people in the United States die of #HepB related liver diseases each year. Check out more statistics here: https://t.co/YqlCbXOSwj #HepatitisAwarenessMonth @cdchep

[CDC Hepatitis @cdchep]

We have viral #hepatitis fact sheets in multiple languages! Visit https://t.co/bX69lGRX76 for fact sheets on #hepB and #hepC! #NOHep #HepAware

[Arbutus Biopharma @ArbutusBio]

For every 1,000 #pregnant women that give birth each year, an estimated 1 to 2 of them have #HepB, which can easily spread to their babies. Learn more here: https://t.co/TBfRl1MUZm #HepatitisAwarenessMonth @cdchep

[NOhep @NO_hep]

There an estimated 237 million people living with #HepB worldwide and yet only 9% of those are aware of their diagnosis. To prevent these people developing liver disease or cancer in the future we must find them and link them to care NOW! #NOhep

[Arbutus Biopharma @ArbutusBio]

#ICYMI $ABUS held a conference call to discuss first quarter 2018 financial results. Check out the recorded webcast here: https://t.co/rnU62qZZof

[Hep B Foundation @HepBFoundation]

Ready to increase awareness of #hepatitis B during #HepatitisAwarenessMonth, but not sure how? Check out our latest blog post about for some tips on how you can get involved this month! https://t.co/P74s0QqlOU #HepatitisAwarenessMonth #AAPIHeritageMonth #APAHM #hepB #hepatitisB

[Arbutus Biopharma @ArbutusBio]

•#HepB is the most common serious liver #infection in the world. An estimated 350 million people worldwide are chronically infected. Learn more here: https://t.co/3wOCLurE71 #HepatitisAwarenessMonth

[NOhep @NO_hep]

It's May! In the US, May is Hepatitis Awareness Month! Follow us and re-tweet us over the coming month to raise awareness that we can #eliminate viral #hepatitis! #NOhep

[Arbutus Biopharma @ArbutusBio]

$ABUS Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results https://t.co/YUh9SfaIA1

[Arbutus Biopharma @ArbutusBio]

#HBV is the cause of up to 80% of #livercancers. Liver cancer patients typically have a five-year survival rate of only 15%. $ABUS is dedicated to finding a cure for #HepB. Learn more from our recent #EASL2018 presentations: https://t.co/5ifv7XBbnB. #ILC2018

[Arbutus Biopharma @ArbutusBio]

$ABUS evaluated the anti-#HBV activities of two novel orally administered agents in combination with standard of care treatment & the investigational RNA interference agent, ARB-1467. Learn more at our #EASL2018 presentation in the session HBV cure: Pre-clinical studies. #ILC2018

[Arbutus Biopharma @ArbutusBio]

Don't miss it! Amy Lee is presenting now on a promising new agent to potentiate HBV cure that acts on multiple #HBV viral transcripts, enabling inhibition of HBV replication and suppression of all viral antigens. #ILC2018

[Arbutus Biopharma @ArbutusBio]

Learn more about a promising new agent to potentiate HBV cure
that acts on multiple #HBV viral transcripts, enabling inhibition of HBV replication and suppression of all viral antigens at our #EASL2018 parallel session oral presentation today. #ILC2018